Cationic antimicrobial peptides: towards clinical applications.
Cationic antimicrobial peptides are important components of the innate immune defences of all species of life. Variants of these natural molecules have a broad range of antibiotic, antifungal, antiviral and anti-endotoxic activity. Two of these cationic peptides have shown signs of efficacy in early clinical trials of oral mucositis and the sterilisation of central venous catheters, respectively and are currently proceeding through Phase III clinical trials. Thus, cationic antimicrobial peptides are currently being investigated as topical agents. In addition, the cationic protein rBPI 21 has recently completed Phase III clinical trials of parenteral use for meningococcaemia.
Hancock
R E
RE
University of British Columbia, 6174 University Boulevard, Vancouver, BC V6T 1Z3, Canada.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002412:Cations; D002986:Clinical Trials as Topic; D006801:Humans; D007239:Infections / Q000188:drug therapy; D010455:Peptides
D000900:Anti-Bacterial Agents; D002412:Cations; D010455:Peptides